EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

22 Apr 2025 07:59:59 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Stock Repurchase Program

31 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

20 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

20 Mar 2025 08:06:17 By Nasdaq GlobeNewswire

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

19 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

18 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

13 Mar 2025 08:29:43 By Nasdaq GlobeNewswire

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

12 Mar 2025 08:00:26 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

10 Mar 2025 09:14:36 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

03 Mar 2025 16:23:25 By Nasdaq GlobeNewswire

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

18 Feb 2025 08:55:56 By Nasdaq GlobeNewswire

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

07 Feb 2025 08:06:54 By Nasdaq GlobeNewswire

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

16 Jan 2025 08:00:03 By Nasdaq GlobeNewswire

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

14 Jan 2025 07:30:34 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

13 Jan 2025 09:27:39 By Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

08 Jan 2025 07:45:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

08 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

16 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

06 Nov 2024 16:49:03 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

06 Nov 2024 16:05:01 By Nasdaq GlobeNewswire